100 related articles for article (PubMed ID: 22573350)
1. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma.
Heemann C; Kreuz M; Stoller I; Schoof N; von Bonin F; Ziepert M; Löffler M; Jung W; Pfreundschuh M; Trümper L; Kube D
Clin Cancer Res; 2012 Jul; 18(13):3637-47. PubMed ID: 22573350
[TBL] [Abstract][Full Text] [Related]
2. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
3. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
4. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
[TBL] [Abstract][Full Text] [Related]
5. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
Lee JJ; Kim DH; Lee NY; Sohn SK; Kim JG; Kim HJ; Do YR; Park YH
Br J Haematol; 2007 May; 137(4):329-36. PubMed ID: 17408400
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women.
Kim H; Chun S; Ku SY; Suh CS; Choi YM; Kim JG
Menopause; 2009; 16(5):1014-20. PubMed ID: 19369902
[TBL] [Abstract][Full Text] [Related]
8. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
[TBL] [Abstract][Full Text] [Related]
9. Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7.
Bortolin MT; Tedeschi R; Bidoli E; Zanussi S; Pratesi C; Vaccher E; Tirelli U; De Paoli P
Cytokine; 2012 Oct; 60(1):90-5. PubMed ID: 22795293
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
Glossop JR; Dawes PT; Nixon NB; Mattey DL
Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis.
Mattey DL; Glossop JR; Nixon NB; Dawes PT
Arthritis Rheum; 2007 Dec; 56(12):3940-8. PubMed ID: 18050238
[TBL] [Abstract][Full Text] [Related]
12. Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis.
Valle Y; Ledezma-Lozano IY; Torres-Carrillo N; Padilla-Gutiérrez JR; Navarro-Hernández RE; Vázquez-Del Mercado M; Palafox-Sánchez CA; Armendáriz-Borunda J; Muñoz-Valle JF
Scand J Rheumatol; 2009; 38(5):332-5. PubMed ID: 19579138
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis.
Kieszko R; Krawczyk P; Chocholska S; Bojarska-Junak A; Jankowska O; Król A; Roliński J; Milanowski J
Respir Med; 2007 Mar; 101(3):645-54. PubMed ID: 16889950
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory cytokines and soluble receptors after coronary artery bypass grafting.
Wei M; Kuukasjärvi P; Laurikka J; Pehkonen E; Kaukinen S; Laine S; Tarkka M
Cytokine; 2001 Aug; 15(4):223-8. PubMed ID: 11563882
[TBL] [Abstract][Full Text] [Related]
17. [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas].
Zhang YJ; Ren ZM; Wu QL; He ZY; Huang Y; Xia YF; Lin TY; Cui NJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Apr; 27(4):217-21. PubMed ID: 16875549
[TBL] [Abstract][Full Text] [Related]
18. Cell dynamics and expression of tumor necrosis factor (TNF)-alpha, interleukin-6, and TNF receptors in angioimmunoblastic lymphadenopathy-type T cell lymphoma.
Yamaguchi S; Kitagawa M; Inoue M; Tomizawa N; Kamiyama R; Hirokawa K
Exp Mol Pathol; 2000 Apr; 68(2):85-94. PubMed ID: 10716912
[TBL] [Abstract][Full Text] [Related]
19. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A
Haematologica; 2004 May; 89(5):552-6. PubMed ID: 15136218
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
